Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

4D 710

Next Previous
Drug Profile

4D 710

Alternative Names: 4D 710

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4D Molecular Therapeutics
  • Class Antifibrotics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cystic fibrosis

Most Recent Events

  • 28 Mar 2024 4D 710 receives Orphan Drug status for Cystic fibrosis in USA
  • 28 Mar 2024 4D Molecular Therapeutics completes discussions with the European Medicines Agency (EMA), regarding the registrational path for 4D 710 for treatment of cystic fibrosis lung disease in pwCF who are ineligible for or cannot tolerate approved CF modulator therapies
  • 28 Mar 2024 4D Molecular Therapeutics completes discussions with the US FDA regarding the registrational path for 4D 710 for treatment of cystic fibrosis lung disease in pwCF who are ineligible for or cannot tolerate approved CF modulator therapies
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top